EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Significance of Inflammation Markers to Predict Curative Treatment for Prostate Cancer Patients on Active Surveillance

Yenigürbüz Serkan iD, Ediz Caner, Akan Serkan, Kati Bulent, Vural Yasin, Alcin Adem, Yilmaz Omer

Journal of Clinical Laboratory Analysis · 2025

DOI: 10.1002/jcla.70059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, 2025. Verfasst von Yenigürbüz Serkan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sultan 2. Abdulhamid Han Education and Research Hospital, Istanbul, Turkey. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Inflammation, Biomarkers, Tumor, Watchful Waiting. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Active surveillance (AS) strategy aims to avoid unnecessary or excessive early treatment in patients at a low risk for prostate cancer (PCa). However, a biomarker that can predict the need for early curative treatment in patients under AS has not been identified to date. In this study, we aimed to investigate the potential of inflammatory biomarkers in predicting the requirement of curative treatment in the early period in patients under AS. Materials and Methods This study included a total of 83 patients with the diagnosis of PCa and under AS. Patient age, prostate‐specific antigen (PSA) level, prostate volume (PV), PSA density (PSAD), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), systemic immune‐inflammation index (SII) and follow‐up period were compared between the groups.

Results

There was a significant difference between the two groups in terms of PSAD, NLR, PLR and SII ( p = 0.037, p = 0.046, p = 0.008, p = 0.004 and p = 0.005, respectively). The cut‐off value determined by performing ROC analysis to evaluate the levels that predict the need for curative treatment before AS was 0.125 for PSAD (sensitivity: 61.8%, specificity: 61.2%), 2.01 for NLR (sensitivity: 67.6%, specificity: 55.1%), 115.49 for PLR (sensitivity: 73.5%, specificity: 59.2%) and 465.40 for SII (sensitivity: 70.6%, specificity: 59.2%).

Conclusions

The analysis of PSAD, NLR, PLR and SII before making the decision to conduct AS can guide clinicians regarding curative treatment in the early period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsInflammationBiomarkers, TumorWatchful WaitingHumansMaleAgedMiddle AgedProstate-Specific AntigenROC CurveNeutrophilsLymphocytes

Stichwörter der Autor:innen

active surveillancebiomarkersinflammation mediatorsprostatic neoplasmstumor

Substanzen

Prostate-Specific AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, Sultan 2. Abdulhamid Han Education and Research Hospital, Istanbul, Turkey.
  • Department of Urology, Fatih Sultan Mehmet Han Education and Research Hospital, Istanbul, Turkey.
  • Department of Urology, Harran University Hospital, Sanliurfa, Turkey.

ORCID-Profile: Yenigürbüz Serkan

Zitieren

APA

Serkan, Y., Caner, E., Serkan, A., Bulent, K., Yasin, V., Adem, A., & Omer, Y. (2025). Significance of Inflammation Markers to Predict Curative Treatment for Prostate Cancer Patients on Active Surveillance. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.70059

Vancouver

Serkan Y, Caner E, Serkan A, Bulent K, Yasin V, Adem A, et al. Significance of Inflammation Markers to Predict Curative Treatment for Prostate Cancer Patients on Active Surveillance. Journal of Clinical Laboratory Analysis. 2025. doi:10.1002/jcla.70059

BibTeX
@article{Serkan2025,
  author = {Serkan, Yenigürbüz and Caner, Ediz and Serkan, Akan and Bulent, Kati and Yasin, Vural and Adem, Alcin and Omer, Yilmaz},
  title = {Significance of Inflammation Markers to Predict Curative Treatment for Prostate Cancer Patients on Active Surveillance},
  journal = {Journal of Clinical Laboratory Analysis},
  year = {2025},
  doi = {10.1002/jcla.70059}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche